
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (date of earliest event reported): August 3, 2003

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Virginia
(State or Other Jurisdiction of
Incorporation)

001-13467
(Commission
File Number)

56-1641133
(I.R.S. Employer
Identification No.)

601 Biotech Drive
Richmond, Virginia 23235
(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (804) 648-3820

ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

On August 3, 2003, the registrant engaged BDO Seidman, LLP to serve as its new independent accountant. Such appointment was approved by the Audit Committee of the registrant's Board of Directors and the Board of Directors.

During the two most recent fiscal years ended December 31, 2001 and December 31, 2002 and through the date of this Form 8-K, neither the registrant, nor anyone on its behalf, has consulted with BDO Seidman, LLP regarding either the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the registrant's financial statements, or any matters or reportable events described under Item 304 (a) (2) of Regulation S-B.

Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly ceased this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Robert B. Harris, Ph.D.

Robert B. Harris, Ph.D.
President and Chief Executive Officer

Date: August 5, 2003